Gout is the most common form of inflammatory arthritis and is a considerable burden to patients and health care systems worldwide. Despite its clinical, economic, and social impact, patient persistence and adherence to prescribed urate-lowering therapies (ULT), ranging from 20% to 70%, is considered to be among the poorest of all chronic conditions. The majority of gout patients consequently receive suboptimal benefits of their prescribed pharmacotherapies. As gout is associated with several comorbidities along with an increased risk of premature mortality, achieving improved outcomes through adherence to ULT is crucial. Adherence to medication is complex and multidimensional and includes a combination of treatment-, patient-, and physician-related factors. This review explores the factors related to ULT adherence with the overall aim of helping health care providers better understand the barriers to adherence. Several interventions targeting pharmacists, nurses, and patients are being investigated to improve adherence. Furthermore, enhanced awareness and understanding of the need to treat-to-target in order to improve patient outcomes is needed among health care professionals. Greater understanding of the multidimensional nature of non-adherence can help physicians to treat gout more effectively and empower patients to improve self-management of this long-term disease.

Improving adherence to gout therapy. an expert review / Perez-Ruiz, Fernando; Desideri, Giovambattista. - In: THERAPEUTICS AND CLINICAL RISK MANAGEMENT. - ISSN 1176-6336. - 14:(2018), pp. 793-802. [10.2147/TCRM.S162956]

Improving adherence to gout therapy. an expert review

Desideri, Giovambattista
2018

Abstract

Gout is the most common form of inflammatory arthritis and is a considerable burden to patients and health care systems worldwide. Despite its clinical, economic, and social impact, patient persistence and adherence to prescribed urate-lowering therapies (ULT), ranging from 20% to 70%, is considered to be among the poorest of all chronic conditions. The majority of gout patients consequently receive suboptimal benefits of their prescribed pharmacotherapies. As gout is associated with several comorbidities along with an increased risk of premature mortality, achieving improved outcomes through adherence to ULT is crucial. Adherence to medication is complex and multidimensional and includes a combination of treatment-, patient-, and physician-related factors. This review explores the factors related to ULT adherence with the overall aim of helping health care providers better understand the barriers to adherence. Several interventions targeting pharmacists, nurses, and patients are being investigated to improve adherence. Furthermore, enhanced awareness and understanding of the need to treat-to-target in order to improve patient outcomes is needed among health care professionals. Greater understanding of the multidimensional nature of non-adherence can help physicians to treat gout more effectively and empower patients to improve self-management of this long-term disease.
2018
gout suppressants; monitoring; persistence; treatment; safety research; pharmacology; toxicology and pharmaceutics (all); pharmacology (medical); chemical health and safety
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Improving adherence to gout therapy. an expert review / Perez-Ruiz, Fernando; Desideri, Giovambattista. - In: THERAPEUTICS AND CLINICAL RISK MANAGEMENT. - ISSN 1176-6336. - 14:(2018), pp. 793-802. [10.2147/TCRM.S162956]
File allegati a questo prodotto
File Dimensione Formato  
Perez-Ruiz_Improving_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 685.08 kB
Formato Adobe PDF
685.08 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1705345
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 24
social impact